|
|
 |
|
Viewing report
|
|
|
|
Company Financials: Micromet
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
Micromet is a biopharmaceutical company focused on developing of novel, proprietary antibody-based products in the therapeutic areas of cancer, inflammatory and autoimmune diseases.
Its lead product candidate, blinatumomab, is in a Phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia and also in a Phase I clinical trial for the treatment of patients with non-Hodgkin's lymphoma.
Key reasons to purchase this title
- Access important financial information and analysis on the company in a single datapack
- Understand the financial evolution of the company over the last five years
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Clinical Operations: Benchmarking Per-Patient Trial Costs, Staffing and Adaptive Design
Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US
Company Financials: Genomic Health
Company Financials: CuraGen Corporation
Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs
Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials
Company Financials: Acadia Pharmaceuticals Inc.
Company Financials: Cougar Biotechnology, Inc.
Company Financials: Dyax Corporation
Company Financials: Idenix Pharmaceuticals, Inc.
|
|
|
|
